pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

456 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT786Endpoints591BioPharma Dive228onclive165BioSpace63Fierce Biotech63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • <![CDATA[FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations]]>
    <![CDATA[Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.]]>
    onclive · 2mo ago↗ source
  • Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 2mo ago↗ source
  • Biotech layoffs are easing, but is the worst over?
    <figure><div><img src="https://imgproxy.divecdn.com/TL3Qf7mHRlVjEhCJI35ocLIfavZ0TUEHiNIVNf4xjm8/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjYtMDUtMDdfYXRfM…
← prev
page 14 of 19
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT]]>
    <![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection]]>
    <![CDATA[In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Expanding ctDNA Applications to RCC and Germ Cell Tumors]]>
    <![CDATA[Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice]]>
    <![CDATA[Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[ctDNA in Metastatic Urothelial Carcinoma]]>
    <![CDATA[Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Institutional Perspectives on Treatment Thresholds in PLGG]]>
    <![CDATA[Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups]]>
    <![CDATA[In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across diffe…
    onclive · 2mo ago↗ source
  • Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies
    <p>The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.</p>
    BioPharma Dive · 2mo ago↗ source
  • The capacity crunch in biopharma is a location problem
    <p>Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change the math on scaling.</p>
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer]]>
    <![CDATA[The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Five Under 5: Top Oncology Videos for the Week of 5/3]]>
    <![CDATA[The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention]]>
    <![CDATA[Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[The OncFive: Top Oncology Articles for the Week of 5/3]]>
    <![CDATA[The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT]]>
    <![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer]]>
    <![CDATA[Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma]]>
    <![CDATA[Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD]]>
    <![CDATA[Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer]]>
    <![CDATA[Capivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[UT MD Anderson Shares Latest Research Breakthroughs]]>
    <![CDATA[The University of Texas MD Anderson Cancer Center released recent oncology research highlights.]]>
    onclive · 2mo ago↗ source
  • Lilly to invest extra $4.5B across Indiana manufacturing
    <figure><div><img src="https://imgproxy.divecdn.com/8nTrHlsFTcngJswJxr_8afos9dxh_YxQE6LZmgMA2_I/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDkyNDczMjEzX2VHa…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Giants of Cancer Care Announces the 14th Annual Class of Inductees ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source